Status and phase
Conditions
Treatments
About
To evaluate TQH2722 injection in all patients receiving background treatment with mometasone furoate nasal spray (MFNS) and loratadine. The efficacy, safety and immunogenicity of the solution in patients with seasonal allergic rhinitis compared with placebo are expected to include 168 patients with confirmed seasonal allergic rhinitis (SAR) who have failed to respond to standard treatments.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
168 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Zheng Liu, Doctor; Rongfei Zhu, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal